- BRCA 1/BRCA 2 Pathogenic/Likely Pathogenic Variant Patients with Breast, Ovarian, and Other Cancers, 2023
- PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score, 2023
- Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study, 2023
- Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study, 2023
- Classifying Invasive Lobular Carcinoma as Special Type Breast Cancer May Be Reducing Its Treatment Success: A comparison of Survival Among Invasive Lobular Carcinoma, Invasive Ductal Carcinoma, and No-Lobular Special Type Breast Cancer, 2023
- External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database, 2023
- Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series, 2022
- The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study, 2022
- Impact of systemic inflammatory markers in patients with ALK-positive non-small cell lung cancer treated with crizotinib, 2022
- Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade, 2022
- Prognostic Factors for Survival in Transverse Colon Cancers, 2022
- ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences, 2022
- Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey, 2022
- Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS), 2022
- Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry, 2022
- An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction, 2022
- Prognostic nutritional index is an independent prognostic factor for treatment response, survival and drug choice in metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide, 2022
- Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series, 2022
- Recurrent delayed immune-related pneumonitis after immune-checkpoint inhibitor therapy for advanced osteosarcoma, 2022
- Comparison of real-life data from patients with NGS panel negative and KRAS mutation positive metastatic lung adenocarcinoma, 2022
- Prognostic nutritional index and its dynamics after curative treatment are independent prognostic factors on survival in non-metastatic nasopharyngeal carcinoma, 2022
- Skeletal muscle loss during anti-epidermal growth factor receptor therapy is an independent prognostic factor on non-small cell lung cancer patients survival., 2021
- Efficacy of regorafenib in the second-and third-line settingfor patients with advanced hepatocellular carcinoma: A reallife data of multicenter study from Turkey, 2020
- The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer, 2020
- Relationship between the Size and Location of the Mass and Hilar and Mediastinal Lymph Node Metastasis in Early and Locally Advanced Non-small Cell Lung Cancer, 2020
- Neutrophil–lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study), 2020
- Neutrophil–lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study), 2020
- Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study), 2020
- Efficacy of Regorafenib in the Second-and Third-line Settingfor Patients with Advanced Hepatocellular Carcinoma: A RealLife Data of Multicenter Study from Turkey, 2020
- Comparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102, 2019
- Regorafenib or rechallenge chemotherapy: Which is more effective in the third-line treatment of metastatic colorectal cancer?, 2019
- Concordance of PD-L1 expression and CD8+ TIL intensity between NSCLC and synchronous brain metastases, 2019
- Is the Charlson Comorbidity Index a Prognostic Indicator for Toxicity and Mortality in Elderly Patients with Locally Advanced Rectal Cancer?, 2019
- Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer, 2019
